Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) — Sponsor Intelligence | 94 EU Trials

Filter these 94 trials by condition, phase, country and more.

Open in Search →

94 Registered trials

46 Recruiting

17 Completed trials

14 Countries active

123 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 15 Phase II/III: 3 Phase II: 17 Phase I/II: 7 Phase III/IV: 8 Phase IV: 27 Phase I: 3 Phase I (Other): 8 Phase I (FiH): 4 Other: 2

Oversight events:

2 serious breaches 1 temporary halt across 3 trials

View oversight register →

100%

17 of 17 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioblastoma multiforme 2 Rheumatoid arthritis 1 Cancer pain 1 Laser speckle contrast imaging 1 Prostate cancer metastatic 1 Complex regional pain syndrome 1 Oxytocin 1 Trigeminal nerve disorder 1 Cardiac sarcoidosis 1 Migraine 1

Top IMPs

IRINOTECAN HYDROCHLORIDE TRIHYDRATE 5 FLUOROURACIL 4 FOLINIC ACID 4 OXALIPLATIN 4 NIVOLUMAB 3 PEMBROLIZUMAB 3 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 2 [AL[18F]F]FAPI-74 2 ALGLUCOSIDASE ALFA 2 AMOXICILLIN 2 AUTOLOGOUS DENDRITIC CELLS LOADED WITH ALLOGENIC ALLOGENEIC LYSATE OF MESOTHELIOMA CELL LINES 2 AVALGLUCOSIDASE ALFA 2

All trials — page 3

94 total

Exploratory Study of CAPEcitabine pharmacokinetics and hand-foot syndrome in CES1 variant carriers: the ESCAPE study Recruiting

2024-516788-96-00 Phase IV 1 country
BuLLSEYE Recruiting

2024-512950-13-00 Phase III/IV 1 country AMOXICILLIN; AMOXICILLIN, AMOXICILLIN, CLAVULANIC ACID, CLAVULANIC ACID; CEFOTAX…
Safe Stop Trial Melanoma Recruiting

2024-516937-10-01 Phase III 1 country NIVOLUMAB; PEMBROLIZUMAB
Efficacy of antibiotic treatment for patients with chronic low back pain Recruiting

2024-515824-35-01 Phase IV 1 country AMOXICILLIN
A Phase-2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Enc… Recruiting

2023-504686-23-00 Phase II 2 countries HUMAN NORMAL IMMUNOGLOBULIN; HUMAN NORMAL IMMUNOGLOBULIN (IV); INEBILIZUMAB
Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance Recruiting

2023-507489-20-00 Phase IV 1 country ROSUVASTATIN CALCIUM
The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study … Recruiting

2023-507938-24-00 Phase III 1 country [AL[18F]F]FAPI-74; GLUCAGON; HYOSCINE BUTYLBROMIDE
MAGE-C2 TCR T cell therapy Recruiting

2024-516922-70-00 Phase I/II 1 country RETROVIRAL VECTOR CONTAINING THE COMMON GAMMA CHAIN CDNA, AUTOLOGOUS TUMOUR-INFI…
Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP) Recruiting

2024-518355-36-01 Phase I 1 country
The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlle… Recruiting

2024-514055-15-00 Phase IV 1 country
CHASIT Recruiting

2024-516940-24-00 Phase II 1 country AVELUMAB
DAROTAXEL Recruiting

2024-516939-28-00 Phase II 1 country CABAZITAXEL; DAROLUTAMIDE; DOCETAXEL
Preventing liver recurrence after partial hepatectomy for intrahepatic cholangiocarcinoma using adjuvant hepatic arterial infusion pump chem… Recruiting

2024-513726-33-00 Phase II 1 country
Safety and efficacy of avalglucosidase alfa in patients with non-classic Pompe disease aged ≥ 5 years. Recruiting

2024-518215-18-00 Phase IV 1 country AVALGLUCOSIDASE ALFA
Bio-equivalence of Rosuvastatin 10 mg Recruiting

2023-509661-21-00 1 country
Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) … Recruiting

2024-517865-17-01 Phase IV 1 country TOFACITINIB
Dendritic cell therapy combined with surgery in mesothelioma (ENSURE) Recruiting

2024-514054-70-00 Phase I 1 country
Research into topiramate to remove the hidden HIV in people living with HIV taking HIV treatment Recruiting

2024-511532-27-00 Phase II 1 country
Pro-RAPID Recruiting

2023-507352-72-00 Phase IV 1 country INFLIXIMAB
Beta receptor modulation trial in cardiogenic shock patients supported by V-A ECMO Recruiting

2024-511805-42-00 Phase II 1 country DOBUTAMINE; ESMOLOL HYDROCHLORIDE; MILRINONE
VulVaccin study Recruiting

2023-506792-94-00 Phase III/IV 1 country HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting

2023-506698-36-00 Phase III 1 country LEUPRORELIN; LEUPRORELIN ACETATE; TRIPTORELIN
Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal ad… Recruiting

2024-514597-42-00 Phase I/II 1 country DURVALUMAB; RINTATOLIMOD
STEPS-EA trial Recruiting

2023-504905-36-00 Phase III/IV 5 countries TRIAMCINOLONE ACETONIDE

Showing 49–72 of 94 trials

← All sponsors A–Z